JWT Hong Kong adds Physiogel to GSK portfolio

GSK has awarded JWT Hong Kong creative duties for Physiogel, the latest in a growing portfolio of brands the pharmaceutical giant has handed the agency over the last year.

JWT Hong Kong, which won Physiogel after a three way pitch earlier this month, won GSK’s Zyrtec in May 2012, followed Avamys, another allergy medicine, and disease education for measles, mumps, rubella and varicella. In August 2012 GSK tapped JWT to created Physiogel AI Cream’s winter campaign for Hong Kong. That initiative was a phenomenal success, helping boost product sales by more than 40% during the life of the campaign.

“According to the latest data, Physiogel is the fastest growing product in April YTD 2013. And it is the first time ever for Physiogel to snatch such a large portion of the market – in both the mass brands market (Ref: AC Nielsen) and the pharmaceutical market (Ref: HKAPI data). I am pleased that our strategy and our close partnership with JWT is bearing fruit,” said Matthew Chan, Dermatology and Vaccines Business Unit Director.

“JWT is highly committed to and passionate about creativity. They work with a strong team spirit, demonstrating an understanding of our brand and products. As a result they are able to provide thoughtful strategic approaches and creative materials to meet our marketing objectives.”

“It’s wonderful to receive yet another vote of confidence from GSK,” said Dennis Wong, JWT Hong Kong CEO. “We have a very passionate team that’s committed to delivering the quality thinking, creative ideas and effective strategies that clients have come to expect when they partner with us to build their brand.”